Nanjing Jiening Pharmaceutical Technology

Nanjing Jiening Pharmaceutical Technology is a clinical-stage biopharmaceutical company based in Nanjing, China, focused on the discovery and development of innovative small molecule therapeutics. The company's primary research efforts target oncology and metabolic diseases, with a particular emphasis on highly selective kinase inhibitors. Its lead candidate, JN-001, is a potent and selective FGFR4 inhibitor currently being evaluated in clinical trials for the treatment of advanced hepatocellular carcinoma. Nanjing Jiening leverages its internal R&D capabilities to advance a pipeline of precision medicines designed to address significant unmet medical needs in the Chinese and global markets.